Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia von Park, Jae H, Rivière, Isabelle, Gonen, Mithat, Wang, Xiuyan, Sénéchal, Brigitte, Curran, Kevin J, Sauter, Craig, Wang, Yongzeng, Santomasso, Bianca, Mead, Elena, Roshal, Mikhail, Maslak, Peter, Davila, Marco, Brentjens, Renier J, Sadelain, Michel

Volltext

Toxicity and management in CAR T-cell therapy von Bonifant, Challice L, Jackson, Hollie J, Brentjens, Renier J, Curran, Kevin J

Volltext

GPRC5D-Targeted CAR T Cells for Myeloma von Mailankody, Sham, Devlin, Sean M., Landa, Jonathan, Nath, Karthik, Diamonte, Claudia, Carstens, Elizabeth J., Russo, Douglas, Auclair, Romany, Fitzgerald, Lisa, Cadzin, Briana, Wang, Xiuyan, Sikder, Devanjan, Senechal, Brigitte, Bermudez, Vladimir P., Purdon, Terence J., Hosszu, Kinga, McAvoy, Devin P., Farzana, Tasmin, Mead, Elena, Wilcox, Jessica A., Santomasso, Bianca D., Shah, Gunjan L., Shah, Urvi A., Korde, Neha, Lesokhin, Alexander, Tan, Carlyn R., Hultcrantz, Malin, Hassoun, Hani, Roshal, Mikhail, Sen, Filiz, Dogan, Ahmet, Landgren, Ola, Giralt, Sergio A., Park, Jae H., Usmani, Saad Z., Rivière, Isabelle, Brentjens, Renier J., Smith, Eric L.

Volltext

IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models von Jaspers, Janneke E, Khan, Jonathan F, Godfrey, William D, Lopez, Andrea V, Ciampricotti, Metamia, Rudin, Charles M, Brentjens, Renier J

Volltext

Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages von Song, Mei, Yeku, Oladapo O., Rafiq, Sarwish, Purdon, Terence, Dong, Xue, Zhu, Lijing, Zhang, Tuo, Wang, Huan, Yu, Ziqi, Mai, Junhua, Shen, Haifa, Nixon, Briana, Li, Ming, Brentjens, Renier J., Ma, Xiaojing

Volltext

Author Correction: T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection von Stephan, Matthias. T, Ponomarev, Vladimir, Brentjens, Renier .J, Chang, Alex. H, Dobrenkov, Konstantin. V, Heller, Glenn, Sadelain, Michel

Volltext

Engineering strategies to overcome the current roadblocks in CAR T cell therapy von Rafiq, Sarwish, Hackett, Christopher S., Brentjens, Renier J.

Volltext

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance von Boyiadzis, Michael M, Dhodapkar, Madhav V, Brentjens, Renier J, Kochenderfer, James N, Neelapu, Sattva S, Maus, Marcela V, Porter, David L, Maloney, David G, Grupp, Stephan A, Mackall, Crystal L, June, Carl H, Bishop, Michael R

Volltext

CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function von Kuhn, Nicholas F., Lopez, Andrea V., Li, Xinghuo, Cai, Winson, Daniyan, Anthony F., Brentjens, Renier J.

Volltext

Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts von BRENTJENS, Renier J, SANTOS, Elmer, NIKHAMIN, Yan, YEN, Raymond, MATSUSHITA, Maiko, LA PERLE, Krista, QUINTAS-CARDAMA, Alfonso, LARSON, Steven M, SADELAIN, Michel

Volltext

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition von Yeku, Oladapo O, Rao, Thapi Dharma, Laster, Ian, Kononenko, Artem, Purdon, Terence J, Wang, Pei, Cui, Ziyou, Liu, Hong, Brentjens, Renier J, Spriggs, David

Volltext

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia von Maslak, Peter G., Dao, Tao, Bernal, Yvette, Chanel, Suzanne M., Zhang, Rong, Frattini, Mark, Rosenblat, Todd, Jurcic, Joseph G., Brentjens, Renier J., Arcila, Maria E., Rampal, Raajit, Park, Jae H., Douer, Dan, Katz, Laura, Sarlis, Nicholas, Tallman, Martin S., Scheinberg, David A.

Volltext

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date von Park, Jae H., Geyer, Mark B., Brentjens, Renier J.

Volltext

CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience von Palomba, M Lia, Qualls, David, Monette, Sebastien, Sethi, Shenon, Dogan, Ahmet, Roshal, Mikhail, Senechal, Brigitte, Wang, Xiuyan, Rivière, Isabelle, Sadelain, Michel, Brentjens, Renier J, Park, Jae H, Smith, Eric L

Volltext

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment von Yeku, Oladapo O., Purdon, Terence J., Koneru, Mythili, Spriggs, David, Brentjens, Renier J.

Volltext

Development of CAR T cells designed to improve antitumor efficacy and safety von Jaspers, Janneke E, Brentjens, Renier J

Volltext

Tumors evading CARs—the chase is on von Rafiq, Sarwish, Brentjens, Renier J.

Volltext

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo von Koneru, Mythili, Purdon, Terence J., Spriggs, David, Koneru, Susmith, Brentjens, Renier J.

Volltext

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Rece... von Park, Jae H, Romero, F Andres, Taur, Ying, Sadelain, Michel, Brentjens, Renier J, Hohl, Tobias M, Seo, Susan K

Volltext

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer von Koneru, Mythili, O’Cearbhaill, Roisin, Pendharkar, Swati, Spriggs, David R, Brentjens, Renier J

Volltext